Prazosin Impurities and Prazosin
Daicel Pharma offers Prazosin impurity standards, including Prazosin Impurity, Prazosin related compound, and Prazosin Intermediate / Doxazosin Intermediate. The presence of these impurities can have a significant impact on the efficacy, quality, and safety of Prazosin. Daicel Pharma custom synthesizes Prazosin impurities and delivers them globally.
Prazosin [CAS: 19216-56-9] belongs to the piperazine class and treats hypertension. Prazosin treats high blood pressure and the symptoms of prostatic hyperplasia.
Prazosin: Use and Commercial Availability
Prazosin is a medication utilized to treat hypertension and belongs to the nonselective alpha-adrenergic antagonists, commonly known as alpha-blockers. It treats hypertension (high blood pressure). Prazosin is used alone or with other blood pressure-lowering medications, such as diuretics or beta-adrenergic-blocking medicines. Prazosin has no detrimental effects on lung function and can thus be used to treat hypertension in people with asthma or chronic obstructive pulmonary disease (COPD). This medication is available under brands such as Minipress and Minipress XL.
Prazosin Structure and Mechanism of Action
The chemical name of Prazosin is [4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanylmethanone. Its chemical formula is C19H21N5O4, and its molecular weight is approximately 383.4 g/mol.
The exact mechanism of action of Prazosin is unknown.
Prazosin Impurities and Synthesis
Like many pharmaceutical compounds, Prazosin can contain impurities, unwanted substances in the drug product. They may arise during manufacturing1 or as degradation products. Common Prazosin impurities include related substances such as unreacted starting materials, intermediates, and their degradation products. Their presence in Prazosin can affect its purity, potency, and safety. Therefore, strict quality control measures are essential to ensure Prazosin purity and integrity and minimize the presence of impurities.
Daicel Pharma provides a Certificate of Analysis (CoA) for Prazosin impurity standards including Prazosin Impurity, Prazosin related compound, and Prazosin Intermediate / Doxazosin Intermediate. At Daicel Pharma, we offer a cGMP-certified analytical laboratory that provides the CoA, which includes thorough characterization data including 1H NMR, 13C NMR, IR, MASS, and HPLC purity2. On request, we give more characterization details, such as those for 13C-DEPT. Our team of experts specializes in synthesizing Prazosin impurities and labeled compounds for evaluating the effectiveness of generic Prazosin. Additionally, Daicel Pharma offers Prazosin -D8, a deuterium-labeled Prazosin standard, crucial for bioanalytical research and Bioavailability/Bioequivalence (BA/BE) studies.
Frequently Asked Questions
Examining Prazosin impurities is necessary to ensure its quality, safety, and efficacy, as they can affect its effectiveness, stability, and potential side effects.
The sources of Prazosin impurities can include starting materials, reagents, reaction intermediates, degradation products, and contamination during synthesis or handling.
The presence of Prazosin impurities can potentially impact drug interactions and the stability of the medication.
One can ensure the quality of Prazosin concerning impurities by procuring it from reputable manufacturers following good manufacturing practices (GMP) and obtaining appropriate analytical documentation.
Prazosin impurities are stored preferably at a regulated room temperature of 2-8°C or as specified on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.